PAVmed (NASDAQ:PAVM) posted its quarterly earnings results on Sunday. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.06), MarketWatch Earnings reports.
NASDAQ:PAVM opened at $5.55 on Tuesday. The firm has a market cap of $399.07 million, a PE ratio of -7.30 and a beta of 0.13. PAVmed has a 12 month low of $1.30 and a 12 month high of $5.63. The company’s 50-day moving average price is $2.59 and its two-hundred day moving average price is $2.08.
Several research firms recently issued reports on PAVM. Lake Street Capital increased their price target on shares of PAVmed from $5.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday. Ascendiant Capital Markets assumed coverage on PAVmed in a report on Thursday, November 5th. They issued a “buy” rating and a $5.00 target price for the company.
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
Further Reading: Euro STOXX 50 Index
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.